Journal
BRAIN INJURY
Volume 19, Issue 7, Pages 471-479Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/02699050400025059
Keywords
amantadine; traumatic brain injury; frontal lobes; executive function; positron emission tomography; dopamine
Categories
Funding
- PHS HHS [100849] Funding Source: Medline
Ask authors/readers for more resources
Primary objective: This study was performed to assess effects of amantadine (AMH), a dopaminergic agent and NMDA antagonist, on chronic traumatic brain injury (TBI). The primary hypotheses were that amantadine treatment would result in executive function improvement and increased activity in pre-frontal cortex. Research design: An open-label design was used. Methods: Twenty-two subjects underwent neuropsychological testing pre- and post-12 week treatment. Six subjects also underwent PET scanning. Intervention: Amantadine 400 mg was administered per day. Results: Significant improvements on tests of executive function were observed with treatment. Analysis of PET data demonstrated a significant increase in left pre- frontal cortex glucose metabolism. There was a significant positive correlation between executive domain scores and left pre- frontal glucose metabolism. Conclusions: This is the first known study to assess amantadine in chronic TBI using PET and the data are consistent with the hypotheses. The conduction of further studies is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available